Breast Cancer, Endometrial Cancer, Ovarian Cancer
Conditions
Brief summary
Patients who were previously enrolled on the LY353381 arm of any LY353381 oncology trial could enroll in this roll-over study if they had exhibited clinical benefit from treatment and wished to continue on treatment. Patients were monitored for safety.
Interventions
DRUGarzoxifene
Sponsors
Eli Lilly and Company
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Healthy volunteers
No
Inclusion criteria
* Participation in a clinical trial of LY353381 that has met its main safety and efficacy objectives, and could otherwise close. * Evidence of continuing benefit with LY353381 (eg. complete response, partial response or stable disease with no symptomatic or clinical evidence of disease progression). * Adequate bone marrow reserve, liver and renal function, consistent with the previous LY353381 protocol, with no recent significant deterioration or metabolic condition that could affect patient safety or compliance with the protocol (eg, hypercalcemia). * Written informed consent from patient. * Childbearing potential either terminated by surgery, radiation, menopause, or attenuated by use of an intra-uterine contraceptive device or barrier method during and for 3 months after the trial.
Exclusion criteria
* No concurrent systemic therapy (immunotherapy, hormone therapy or chemotherapy) for cancer. Palliative radiotherapy is allowed (eg, for pain) as long as there is no evidence of disease progression. Investigational agents, other than LY353381, within the 4 weeks prior to this study enrollment and other SERMs are also not permitted. * No concurrent use of oral contraceptives, GnRH agonists, or coumarin (warfarin). * No serious concomitant systemic disorders incompatible with the study (at the discretion of investigator), including predisposition to thromboembolic disorder. * Must not be pregnant or breast-feeding. * Must not have a gap in treatment of more than 4 weeks between previous LY353381 study and enrollment in current study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To allow continued treatment of patients who exhibited clinical benefit from arzoxifene | — |
Secondary
| Measure | Time frame |
|---|---|
| To collect long-term safety data on arzoxifene use in advanced cancer patients | — |
Countries
United States
Outcome results
None listed